Altimmune (NASDAQ:ALT) Announces Quarterly Earnings Results

Altimmune (NASDAQ:ALT) released its quarterly earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, FiscalAI reports. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%.

Here are the key takeaways from Altimmune’s conference call:

• Altimmune said it raised $225 million in an oversubscribed April offering, bringing pro forma cash to about $535 million and funding the company through the expected 2029 Phase III MASH 52-week data readout.
• The company said its global Phase III MASH study, PERFORMA, is on track to start in the second half of 2026, with the protocol finalized and aligned with both the FDA and EMA.
• Management emphasized pemvidutide’s potential differentiation in MASH, pointing to a favorable tolerability profile, simple titration, sustained weight loss, and possible preservation of lean muscle mass versus some competing GLP-1-based therapies.
• Altimmune said the 48-week Phase II IMPACT results will be presented orally at EASL, including additional fibrosis analysis and other biomarker data, which the company said should reinforce interest in the program.
• Beyond MASH, Altimmune remains on track to report Phase II AUD top-line data next quarter and expects to complete enrollment in the ALD RESTORE trial in the third quarter of 2026.

Altimmune Price Performance

Shares of NASDAQ ALT traded down $0.06 during trading hours on Wednesday, reaching $3.02. 3,575,240 shares of the stock traded hands, compared to its average volume of 4,538,451. The company’s 50-day simple moving average is $3.34 and its two-hundred day simple moving average is $4.12. The company has a market capitalization of $392.90 million, a P/E ratio of -2.99 and a beta of 0.18. Altimmune has a 52-week low of $2.56 and a 52-week high of $7.73. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.15.

Insider Transactions at Altimmune

In other Altimmune news, CEO Jerome Benedict Durso purchased 20,000 shares of Altimmune stock in a transaction on Friday, March 6th. The shares were acquired at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently made changes to their positions in ALT. Arax Advisory Partners grew its holdings in shares of Altimmune by 99.7% during the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Altimmune in the fourth quarter worth $36,000. CreativeOne Wealth LLC bought a new stake in Altimmune in the fourth quarter worth $38,000. Victory Capital Management Inc. purchased a new stake in Altimmune during the third quarter valued at about $38,000. Finally, BNP Paribas Financial Markets boosted its position in Altimmune by 108.5% during the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after buying an additional 5,253 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. B. Riley Financial decreased their target price on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Wall Street Zen lowered Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Friday, March 27th. HC Wainwright raised their target price on shares of Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Finally, Barclays initiated coverage on shares of Altimmune in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price target for the company. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.